ACER Insider Trading Activity and SEC Form 4 Filings
ACER insider trading summary
No open-market insider purchases or sales of Acer Therapeutics Inc. (ACER) have been reported on SEC Form 4 in the past 12 months.
Latest ACER insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 29, 2022 | Chris Schelling | President & CEO | Buy | $1000K (819,672 @ $1.22) |
| Nov 29, 2022 | Steve Aselage | Director | Buy | $500K (409,836 @ $1.22) |
| Dec 10, 2021 | Steve Aselage | Director | Buy | $16K (7,984 @ $2.04) |
| Dec 9, 2021 | Steve Aselage | Director | Buy | $4K (2,016 @ $2.15) |
| Jul 24, 2020 | Steve Aselage | Director | Buy | $158K (45,000 @ $3.50) |
| Jul 24, 2020 | John Michael Dunn | Director | Buy | $75K (21,428 @ $3.50) |
| Jul 24, 2020 | Donald Joseph | Chief Legal Officer and Secy | Buy | $50K (14,285 @ $3.50) |
| Jul 24, 2020 | Chris Schelling | President & CEO | Buy | $500K (142,857 @ $3.50) |
| Jul 3, 2019 | Steve Aselage | Director | Buy | $19K (5,000 @ $3.72) |
| Aug 1, 2018 | TVM Life Science Ventures VII L.P. | Director | Buy | $5.0M (275,000 @ $18.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.